Aligos Therapeutics, Inc.ALGS

Aligos Therapeutics, Inc. reported a net income loss of $23.0M for the period ending 2026-03-31. The company's cash and cash equivalents stood at $30.0M, and the short-term investments were $24.9M. The revenue from contract with customer, excluding assessed tax, was $2.8M.

The company is a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases. The amendment to the Aligos Therapeutics, Inc. 2020 Employee Stock Purchase Plan suggests that the company is more focused on rewarding its employees than generating revenue.

The press release dated May 7, 2026, reported recent business progress and first quarter 2026 financial results. The company's operating income loss stood at $26.9M, and the net cash provided by operating activities was $-23.1M. The research and development expense was $23.4M, and the earnings per share, diluted, was $-2.21.

The company's assets stood at $64.6M, and the liabilities were $32.8M. The stockholders' equity attributable to parent was $31.8M. The weighted average number of shares outstanding, diluted, was 10.4M shares.

The company's financial performance raises questions about its ability to deliver on its promises. The disparity between potential and actual revenue, and the gap between the board's incentives and the actual cash collected, are areas of concern.